"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

A study conducted bà Cattolica in Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has uncovered a ...

Alzheimer’s disease remains one of the most pressing challenges in modern medicine, ranking as a leading cause of death ...

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as 'Alzheimer's in a dish,' the model uses cultures of mature brain cells suspended in a gel to recapitulate ...

Scientists have created a game-changing 'Alzheimer's in a dish' model that allows for faster and more accurate testing of ...

Taking medications like blood pressure and lipid-lowering drugs for more than 5 years is associated with a lower incidence of ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...